Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a range of cardiopulmonary and vascular complications, ranging from upper respiratory tract symptoms to severe acute respiratory distress syndrome (ARDS), as well as shock, acute kidney injury, and thromboembolic complications ([@bib1], [@bib2]). Although SARS-CoV-2 initially infects the upper respiratory tract epithelia, some of the most serious complications of the disease appear to arise through vascular inflammation and injury. Although further mechanistic and epidemiological studies are needed, case reports, imaging studies, and autopsy series have suggested the possibility that the SARS-CoV-2 virus, once in the lower respiratory tract, may directly infect endothelial cells, leading to a cascade of consequences including vasoplegia, vascular thromboses, pulmonary edema, endothelial sloughing, and abnormal regulation of pulmonary perfusion ([@bib2], [@bib3]). Regardless of the mechanisms, it is clear that patients often develop severe respiratory failure with hypoxemia that may be refractory to oxygen supplementation and often requires invasive mechanical ventilation. Because of the rapidity with which the virus spread, many healthcare systems were stressed by the sudden increase in coronavirus disease (COVID-19) cases, with the accompanying increased need for hospital beds, ICU beds, ventilators, and even oxygen. A high percentage of mechanically ventilated patients develop multi-organ failure syndrome, characterized by pressor-dependent shock and a high associated mortality. Even those who survive with the assistance of mechanical ventilation may require prolonged hospitalizations ([@bib4]). These concerted adverse sequalae of SARS-CoV-2 infection create major strains on health care system resources.

It is with this backdrop that, in this issue of the *Journal*, Zamanian and colleagues (pp. [130--132](10.1164/rccm.202004-0937LE)) present an interesting and compelling case of a patient with pulmonary arterial hypertension (PAH) who was treated remotely in an ambulatory setting with inhaled nitric oxide (iNO) ([@bib5]). This patient with well-controlled vasoreactive PAH lived in a remote area more than 300 miles away from their center and experienced symptoms of worsening breathlessness after being diagnosed with COVID-19. Considering her concerns about traveling the long distance to their center to receive care, and with recognition of her prior confirmed responsiveness to iNO, they established a plan to support her with an ambulatory iNO system while monitoring her symptoms, vital signs, and functional capacity remotely. The patient had rapid and sustained improvement in her 6-minute-walk distance, as assessed by her caregiver, and symptom score, and she recovered over several days without having to engage emergency department or hospital care.

This case report raises many questions. How might iNO have benefited this patient? Would we expect the benefit to be unique to iNO, or could other therapies that increase signaling along the NO axis also be helpful, such as NO donors, NO precursors, or phosphodiesterase 5 inhibitors? Can NO be safely administered to a patient in their own home, potentially helping to unburden overwhelmed healthcare systems?

NO is a free radial gas that functions as an important signaling molecule in human physiology. Its canonical receptor, guanylate cyclase, is highly expressed vascular smooth muscle cells, where it becomes activated once NO binds to its heme moiety, significantly increasing its enzymatic conversion of guanosine-5′-triphosphate to cyclic guanosine monophosphate, which subsequently promotes vasorelaxation. As a gas, it has unique pharmacological properties including its delivery into well-ventilated lung units where it promotes local vasodilatation. When NO enters the blood stream, it rapidly reacts with intraerythrocytic Hb, thus inactivating the NO, resulting in an extremely short half-life, which limits its systemic effects. By preferentially vasodilating pulmonary arterioles in well-ventilated lung units, it decreases the relative blood flow to poorly ventilated lung units and enhances $\overset{.}{V}/\overset{.}{Q}$ matching, increasing oxygenation ([@bib6]). NO also induces mild bronchodilation, and inhibits neutrophil-mediated oxidative burst ([@bib6]). These properties have been well known for decades and have led to U.S. Food and Drug Administration approval for the treatment of persistent pulmonary hypertension of the newborn, as well as various trials of iNO for patients with myriad conditions including ARDS, right ventricular failure after cardiac surgery, acute pulmonary embolism, and more recently pulmonary fibrosis in patients requiring long-term oxygen therapy ([@bib6]--[@bib10]). In patients with SARS, iNO was associated with improvements in oxygenation in a severity-matched observational cohort ([@bib11]). Both endogenous and exogenous NO were shown to inhibit SARS-CoV viral replication ([@bib12]). While iNO has not been shown to reduce the time on mechanical ventilation or mortality in adults with ARDS, iNO does significantly improve oxygenation in ARDS patients and leads to reduction in pulmonary vascular resistance ([@bib6]) ([Figure 1](#fig1){ref-type="fig"}). These therapeutic responses suggest that iNO could be used early in the course of COVID-19 infection to reduce the need for invasive mechanical ventilation. Studies of prone positioning and neuromuscular blockers in ARDS both provide a historical reminder of that potential, as clinical trials of early delivery of those therapies demonstrated benefits where prior studies had not ([@bib13], [@bib14]).

![Summary of major therapeutic properties of inhaled nitric oxide gas (NO). From top left: inhaled NO gas is known to be a selective pulmonary vasodilator. NO can improve right heart function and decrease pulmonary vasoconstriction in subjects with acute and chronic pulmonary hypertension. Middle left vignette: breathing NO gas is shown to improve ventilation and provide bronchodilation in mild asthmatic subjects. Bottom left vignette: NO gas in the alveolar space improves oxygenation by increasing blood flow to ventilated lung units (i.e., improvement of ventilation perfusion matching). Top and middle right vignettes: *in vitro* and *in vivo* data showed that NO gas can act as an antiinflammatory and antithrombotic agent. Bottom right vignette: NO donors and NO gas showed antibacterial and antiviral properties in *in vitro* studies and early clinical investigations. The extent of benefits of these six therapeutic pathways of NO gas in coronavirus disease (COVID-19) infection are now under investigation. Some of those studies testing NO therapeutic properties are highlighted in [Table 1](#tbl1){ref-type="table"}.](rccm.202005-1906EDf1){#fig1}

Zamanian's case also highlights the feasibility of portable iNO delivery systems to treat patients at home, an option not previously available. While GENOSYL DS (VERO Biotech) is designed for the hospital intensive care setting, it has features, such as a tankless delivery system, that make it feasible to deliver at home, as demonstrated in this case. Other systems, such as INOpulse (Bellerophon Therapeutics), Nu-Med Plus (UT), and an iridium electric NO generator (Third Pole Therapeutics), have been designed with at least some degree of portability. Although there would be concerns in treating patients with a therapy like iNO at home, there is precedent. In a randomized and placebo-controlled trial of ambulatory patients with fibrotic lung disease requiring long-term oxygen, INOpulse therapy was associated with greater physical activity than placebo, and in an acute dose escalation study of patients with pulmonary hypertension associated with pulmonary fibrosis, iNO delivered through the INOpulse system lead to a 30% reduction in pulmonary vascular resistance, with improvements in $\overset{˙}{Q}$ and pulmonary artery compliance ([@bib15]).

It is important to recognize that the experience of Dr. Zamanian's patient is unlikely to be representative of all patients with COVID-19, or even those with PAH complicated by COVID-19. This patient had an established diagnosis of vasoreactive PAH, and as a physician herself, was uniquely qualified to engage in a complex treatment regimen. But the example serves as an interesting proof-of-concept study that supports the rationale of studying iNO therapy in patients with COVID-19 to establish if this intervention can improve oxygenation and reduce need for mechanical ventilation. In [Table 1](#tbl1){ref-type="table"}, we have summarized planned and ongoing clinical trials available that are testing NO gas therapy in COVID-19 patients. Dr. Zamanian and colleagues are to be commended for their innovative approach and important contribution to this field.

###### 

Ongoing Clinical Trials Registered on [clinicaltrials.gov](http://clinicaltrials.gov) Testing NO Gas in COVID-19 Infection

  Short Title                                                   PI                 Coordinating Center                  Study Design            Drug     Dose (*ppm*)                 Duration               Subjects (*n*)        Study Status        Follow-up (*d*)                          Detailed Protocol                                            Primary Endpoint                              Secondary Endpoint            NCT Number
  ------------------------------------------------------ ----------------- ------------------------------------ ----------------------------- -------- ----------------- ---------------------------------- ---------------- ------------------------ ----------------- ----------------------------------------------------------------- ------------------------------------------------------- ------------------------------------- -------------
  NO Therapy: Healthcare Providers                         Lorenzo Berra               MGH, Boston               Multicenter, open-label RCT   NO gas         160                15 min twice daily               470               Recruiting               14          <https://www.medrxiv.org/content/10.1101/2020.04.05.20054544v1>      Prevention of COVID-19 in healthcare providers       \(I\) Prevention to become positive   NCT04312243
  \(II\) Number of quarantine days                                                                                                                                                                                                                                                                                                                                                                                                      
  NO Therapy: COVID-19 Infection in ED                     Stuart Harris               MGH, Boston                           RCT               NO gas         250               30 min, single dose               260               Recruiting               28                                   Not available                                      Rates of return visits to the ED                \(I\) Inpatient hospitalization     NCT04338828
  \(II\) Rates of intubation                                                                                                                                                                                                                                                                                                                                                                                                            
  \(III\) Mortality                                                                                                                                                                                                                                                                                                                                                                                                                     
  NO Therapy: Spontaneous Breathing COVID-19 Infection     Lorenzo Berra               MGH, Boston               Multicenter, open-label RCT   NO gas         160                30 min twice daily               240               Recruiting               28          <https://www.medrxiv.org/content/10.1101/2020.03.10.20033522v1>         Prevention of progression of the disease              \(I\) Antimicrobial effect        NCT04305457
  \(II\) Other clinical outcomes                                                                                                                                                                                                                                                                                                                                                                                                        
  NO Therapy: Ventilated Patients with COVID-19            Lorenzo Berra               MGH, Boston               Multicenter, open-label RCT   NO gas   Initial dose 80     Continuous until extubation           200               Recruiting               90          <https://www.medrxiv.org/content/10.1101/2020.03.09.20033530v1>              Sustained improved oxygenation                  \(I\) Time to reach normoxia       NCT04306393
  \(II\) Other clinical outcome                                                                                                                                                                                                                                                                                                                                                                                                         
  High-Dose NO for COVID-19 (ICU Patients)                Jennifer Lister   University Health Network, Toronto   Multicenter, open-label RCT   NO gas         160                   6 h for 2 d                    20           Not yet recruiting            3                                   Not available                                           Rate of PCR positivity                              Not available              NCT04383002
  The NO-COVID-19 Study                                    Marvin Kostam       Tufts Medical Center, Boston            Open-label RCT          NO gas         20                   Not available                   42           Not yet recruiting           28                                   Not available                                  Prevention of progression of the disease            \(I\) Prevention of progression     NCT04388683
  \(II\) Clinical improvement                                                                                                                                                                                                                                                                                                                                                                                                           
  Pulsed NO in Mild or Moderate COVID-19                   Hunter Gilles              Not available                    Expanded access         NO gas         20                        14 d                 Not available          Recruiting               28                                   Not available                                  Prevention of progression of the disease                     Not available              NCT04358588
  Randomized Trial of INOpulse for COVID-19                Roger Alvarez     Miller School of Medicine, Miami      Placebo- controlled RCT     NO gas         40          To resolution of acute hypoxemia         30           Not yet recruiting            2                                   Not available                                           Safety and tolerability                    \(I\) Prevention of progression     NCT04398290
  \(II\) Clinical improvement                                                                                                                                                                                                                                                                                                                                                                                                           
  NO Releasing Solutions to Prevent and Treat COVID-19      Jeremy Road           BC Diabetes Vancouver                Multicenter RCT          NORS     Not available                   14                       200               Recruiting               21                                   Not available                            Prevention of COVID-19 and progression of the disease     \(I\) Prevention of progression     NCT04337918
  \(II\) Antimicrobial effect                                                                                                                                                                                                                                                                                                                                                                                                           
  NO Treatment for Lung Infections                          Jeremy Road          Diamond Centre Vancouver           Sequential assignment      NO gas         160                  Not available                   20         Active, not recruiting         26                                   Not available                                                   Safety                                   \(I\) Lung function           NCT03331445
  \(II\) Antimicrobial effect                                                                                                                                                                                                                                                                                                                                                                                                           
  \(III\) Quality of life                                                                                                                                                                                                                                                                                                                                                                                                               

*Definition* *of abbreviations*: BC = British Columbia; COVID-19 = coronavirus disease; ED = emergency department; MGH = Massachusetts General Hospital; NO = nitric oxide; NORS = NO-releasing solution; PI = principal investigator; RCT = randomized controlled trial.
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